Brief: Cantargia: Positive Safety Data From Cirifour Study On Nadunolimab, Pembrolizumab Combination

Cantargia AB

03/02/2022 08:36

Feb 3 (Reuters) - Cantargia AB  CANTA.ST :
    * REPORTS POSITIVE SAFETY DATA FROM CIRIFOUR CLINICAL STUDY ON NADUNOLIMAB AND PEMBROLIZUMAB
COMBINATION
    * AS ONE THIRD OF PATIENTS ARE STILL ON THERAPY, EFFICACY IS PLANNED TO BE REPORTED IN Q2
2022

Source text for Eikon:  ID:nWkrYqFgF 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))